Aim immunotech receives erasmus medical center ethics board authorization for phase 2 study of ampligen® for the treatment of locally advanced pancreatic cancer

Ocala, fla., jan. 24, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced that it has received authorization from the erasmus medical center (“erasmus mc”) ethics committee to open a european site for the ongoing phase 2 study (“amp-270”) of ampligen as a therapy for locally advanced pancreatic cancer.
AIM Ratings Summary
AIM Quant Ranking